Sébastien Maury
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sébastien Maury has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
- Catherine Cordonnier
Haematology Department, Henri Mondor Hospital, Assistance Publique-Hopitaux de Paris, Créteil, France; University Paris-Est Créteil, Créteil, France
3 shared publications - Cécile Pautas
Hôpital Henri Mondor, Créteil, France
3 shared publications - David Klatzmann
Immunology, Immunopathology, Immunotherapy i3 Lab, INSERM UMRS-959, Sorbonne Université
3 shared publications - Michelle Rosenzwajg
Sorbonne Université, INSERM, Immunoregulation-Immunopathology-Immunotherapy Lab (i3), Paris, France
3 shared publications C Cordonnier
1] AP-HP, Hôpital Henri Mondor, Department of Hematology, DHU Virus-Immunity-Cancer, Créteil, France [2] IMRB, University Paris Est Créteil (UPEC), INSERM U955 team 21, Créteil, France
2 shared publicationsCatherine Cordonnier
Department of Hematology, AP-HP, Hôpital Henri Mondor, DHU Virus-Immunity-Cancer, Créteil, France
2 shared publications
Latest Publications
- Open Access
- 1 February 2016
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 22 (2) , 292-299
Donor Immunization Against Human Leukocyte Class II Antigens is a Risk Factor for Graft-versus-Host Disease
- 1 February 2016
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 22 (2) , 292-299
Open AccessDonor Immunization Against Human Leukocyte Class II Antigens is a Risk Factor for Graft-versus-Host Disease
- Open Access
- 8 August 2014
- Published by Springer Nature in Leukemia
- Vol. 28 (12) , 2406-2410
Lymphodepletion followed by infusion of suicide gene-transduced donor lymphocytes to safely enhance their antitumor effect: a phase I/II study
- 8 August 2014
- Published by Springer Nature in Leukemia
- Vol. 28 (12) , 2406-2410
Open AccessLymphodepletion followed by infusion of suicide gene-transduced donor lymphocytes to safely enhance their antitumor effect: a phase I/II study
- 25 March 2014
- Published by Wiley in British Journal of Haematology
- Vol. 166 (3) , 452-455
Regulatory T‐cell depletion in donor lymphocyte infusions for haematological malignancies: long‐term outcomes from a prospective study
- 25 March 2014
- Published by Wiley in British Journal of Haematology
- Vol. 166 (3) , 452-455
Regulatory T‐cell depletion in donor lymphocyte infusions for haematological malignancies: long‐term outcomes from a prospective study
- Open Access
- 27 June 2013
- Published by Wiley in American Journal of Hematology
- Vol. 88 (10) , 868-873
Outcome of patients activating an unrelated donor search for severe acquired aplastic anemia
Patients with severe aplastic anemia (SAA) without a sibling donor receive immunosuppressive treatment (IST) with anti‐thymocyte globulin (ATG). In the case of no response to IST, a voluntary unrelated donor (VUD) search is usually started. This study analyzes the outcome of ATG‐refractory SAA patients activating a VUD search. Of 179 patients, 68 had at least one HLA‐A, –B, and –DR matched donor identified and underwent HSCT while 50 also with a donor were not transplanted because of early death (8), late response to IST (34), transplant refusal (1), or other (7). Conversely, 61 had no matched donor, 13 of those ultimately received a mismatched HSCT. All but one received marrow stem cells. Among patients aged P = 0.01). There was also a survival advantage independent of recipient age when the donor search was initiated in the recent 2000–2005 study‐period (74% ± 6% versus 47% ± 10%, P < 0.05). In multivariate analysis, the identification of a matched VUD tended to impact favourably on survival in patients with a recent donor search (P = 0.07). This study provides evidence for the use of unrelated donor HSCT in children and adults with IST‐refractory SAA. Am. J. Hematol. 88:868–873, 2013. © 2013 The Authors. American Journal of Hematology published by Wiley Periodicals, Inc.
- 27 June 2013
- Published by Wiley in American Journal of Hematology
- Vol. 88 (10) , 868-873
Open AccessOutcome of patients activating an unrelated donor search for severe acquired aplastic anemia
Patients with severe aplastic anemia (SAA) without a sibling donor receive immunosuppressive treatment (IST) with anti‐thymocyte globulin (ATG). In the case of no response to IST, a voluntary unrelated donor (VUD) search is usually started. This study analyzes the outcome of ATG‐refractory SAA patients activating a VUD search. Of 179 patients, 68 had at least one HLA‐A, –B, and –DR matched donor identified and underwent HSCT while 50 also with a donor were not transplanted because of early death (8), late response to IST (34), transplant refusal (1), or other (7). Conversely, 61 had no matched donor, 13 of those ultimately received a mismatched HSCT. All but one received marrow stem cells. Among patients aged P = 0.01). There was also a survival advantage independent of recipient age when the donor search was initiated in the recent 2000–2005 study‐period (74% ± 6% versus 47% ± 10%, P < 0.05). In multivariate analysis, the identification of a matched VUD tended to impact favourably on survival in patients with a recent donor search (P = 0.07). This study provides evidence for the use of unrelated donor HSCT in children and adults with IST‐refractory SAA. Am. J. Hematol. 88:868–873, 2013. © 2013 The Authors. American Journal of Hematology published by Wiley Periodicals, Inc.
- Open Access
- 10 December 2012
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 48 (2) , 196-197
Management of adult patients older than 40 years refractory to at least one immunosuppressive course: HLA-identical sibling HSCT using fludarabine-based conditioning
- 10 December 2012
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 48 (2) , 196-197
Open AccessManagement of adult patients older than 40 years refractory to at least one immunosuppressive course: HLA-identical sibling HSCT using fludarabine-based conditioning
- Open Access
- 21 November 2012
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 68 (4) , 943-946
A new workflow for the microbiological diagnosis of febrile neutropenia in patients with a central venous catheter
We aimed to improve the microbial diagnosis of first episodes of febrile neutropenia (FEFNs) since 2 = 0.67, P = 0.41). Direct DNA detection was positive in nine episodes (7.5%) that were also positive in BC. The new workflow provided microbiological results significantly earlier than the standard workflow, with a shorter time to BC positivity (median 12 h 31 min, range 7 h 55 min–25 h 37 min versus median 13 h 01 min, range 9 h 31 min–43 h 33 min, P = 0.004) and shorter turnaround times for identification and susceptibility testing, with most of the results obtained <24 h after BC sampling. We retrospectively estimated that the new workflow would lead to earlier adequacy of antimicrobial therapy in 30% of documented cases. Our new process improved the microbiological diagnosis in FEFNs. Cost effectiveness needs to be tested.
- 21 November 2012
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 68 (4) , 943-946
Open AccessA new workflow for the microbiological diagnosis of febrile neutropenia in patients with a central venous catheter
We aimed to improve the microbial diagnosis of first episodes of febrile neutropenia (FEFNs) since 2 = 0.67, P = 0.41). Direct DNA detection was positive in nine episodes (7.5%) that were also positive in BC. The new workflow provided microbiological results significantly earlier than the standard workflow, with a shorter time to BC positivity (median 12 h 31 min, range 7 h 55 min–25 h 37 min versus median 13 h 01 min, range 9 h 31 min–43 h 33 min, P = 0.004) and shorter turnaround times for identification and susceptibility testing, with most of the results obtained <24 h after BC sampling. We retrospectively estimated that the new workflow would lead to earlier adequacy of antimicrobial therapy in 30% of documented cases. Our new process improved the microbiological diagnosis in FEFNs. Cost effectiveness needs to be tested.
- 11 May 2012
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 97 (11) , 1678-1685
Depletion of T regulatory cells through selection of CD127-positive cells results in a population enriched in memory T cells: implications for anti-tumor cell therapy
Background Donor lymphocyte infusions can induce remissions in patients with relapse after allogeneic hematopoietic stem cell transplantation. Nevertheless, some grafted patients never display any signs of alloreactivity, either following allogeneic hematopoietic stem cell transplantation or after donor lymphocyte infusions. Consequently, they do not develop graft-versus-host disease and frequently do not respond to donor lymphocyte infusions. In a recently published clinical trial, we observed that elimination of CD4+CD25+Foxp3+ natural regulatory T cells from the donor lymphocyte product could improve alloreactivity and the associated anti-tumor effect in a small proportion of patients with relapsed hematologic malignancies. Here, we aimed to improve the effect of donor lymphocyte infusion by modifying the procedure for depletion of T regulatory cells. Design and Methods We directly compared depletion of regulatory T cells from human peripheral blood mononuclear cells achieved by selection of CD127-positive cells or by selection of CD25-negative cells. We tested the manipulated products (i) in vitro in mixed lymphocyte reactions and against pathogen-derived recall antigens and (ii) in vivo in experimental graft-versus-host disease. Results In vitro, we found that depletion of regulatory T cells through CD127 positive selection improved both alloreactive and pathogen-specific immune responses. In vivo, we observed accelerated donor T-cell division and enhanced graft-versus-host disease due to efficient regulatory T-cell depletion accompanied by enrichment in memory T cells. Conclusions Our results show that the strategy of CD127 positive selection is an efficient way of eliminating regulatory T cells from donor lymphocyte infusions and improves alloreactivity. This supports the investigation of CD127 positive selection in place of elimination of CD25-positive cells for clinical applications.
- 11 May 2012
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 97 (11) , 1678-1685
Depletion of T regulatory cells through selection of CD127-positive cells results in a population enriched in memory T cells: implications for anti-tumor cell therapy
Background Donor lymphocyte infusions can induce remissions in patients with relapse after allogeneic hematopoietic stem cell transplantation. Nevertheless, some grafted patients never display any signs of alloreactivity, either following allogeneic hematopoietic stem cell transplantation or after donor lymphocyte infusions. Consequently, they do not develop graft-versus-host disease and frequently do not respond to donor lymphocyte infusions. In a recently published clinical trial, we observed that elimination of CD4+CD25+Foxp3+ natural regulatory T cells from the donor lymphocyte product could improve alloreactivity and the associated anti-tumor effect in a small proportion of patients with relapsed hematologic malignancies. Here, we aimed to improve the effect of donor lymphocyte infusion by modifying the procedure for depletion of T regulatory cells. Design and Methods We directly compared depletion of regulatory T cells from human peripheral blood mononuclear cells achieved by selection of CD127-positive cells or by selection of CD25-negative cells. We tested the manipulated products (i) in vitro in mixed lymphocyte reactions and against pathogen-derived recall antigens and (ii) in vivo in experimental graft-versus-host disease. Results In vitro, we found that depletion of regulatory T cells through CD127 positive selection improved both alloreactive and pathogen-specific immune responses. In vivo, we observed accelerated donor T-cell division and enhanced graft-versus-host disease due to efficient regulatory T-cell depletion accompanied by enrichment in memory T cells. Conclusions Our results show that the strategy of CD127 positive selection is an efficient way of eliminating regulatory T cells from donor lymphocyte infusions and improves alloreactivity. This supports the investigation of CD127 positive selection in place of elimination of CD25-positive cells for clinical applications.
- 13 December 2010
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 46 (10) , 1393-1394
Clofarabine as a potential stimulant of alloreactivity
- 13 December 2010
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 46 (10) , 1393-1394
Clofarabine as a potential stimulant of alloreactivity
- 21 July 2010
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 2 (41) , 41ra52
CD4 + CD25 + Regulatory T Cell Depletion Improves the Graft-Versus-Tumor Effect of Donor Lymphocytes After Allogeneic Hematopoietic Stem Cell Transplantation
Donor T cells play a pivotal role in the graft-versus-tumor effect after allogeneic hematopoietic stem cell transplantation. Regulatory T cells (Tregs) may reduce alloreactivity, the major component of the graft-versus-tumor effect. In the setting of donor lymphocyte infusion after hematopoietic stem cell transplantation, we postulated that Treg depletion could improve alloreactivity and likewise the graft-versus-tumor effect of donor T cells. The safety and efficacy of Treg-depleted donor lymphocyte infusion was studied in 17 adult patients with malignancy relapse after hematopoietic stem cell transplantation. All but one had previously failed to respond to at least one standard donor lymphocyte infusion, and none had experienced graft-versus-host disease. Two of the 17 patients developed graft-versus-host disease after their first Treg-depleted donor lymphocyte infusion and experienced a long-term remission of their malignancy. Four of the 15 patients who did not respond after a first Treg-depleted donor lymphocyte infusion received a second Treg-depleted donor lymphocyte infusion combined with lymphodepleting chemotherapy aimed to also eliminate recipient Tregs. All four developed acute-like graft-versus-host disease that was associated with a partial or complete and durable remission. In the whole cohort, graft-versus-host disease induction through Treg depletion was associated with improved survival. These results suggest that Treg-depleted donor lymphocyte infusion is a safe, feasible approach that induces graft-versus-host or graft-versus-tumor effects in alloreactivity-resistant patients. In patients not responding to this approach, the combination of chemotherapy-induced lymphodepletion of the recipient synergizes with the effect of Treg-depleted donor lymphocyte infusion. These findings offer a rational therapeutic approach for cancer cellular immunotherapy.
- 21 July 2010
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 2 (41) , 41ra52
CD4 + CD25 + Regulatory T Cell Depletion Improves the Graft-Versus-Tumor Effect of Donor Lymphocytes After Allogeneic Hematopoietic Stem Cell Transplantation
Donor T cells play a pivotal role in the graft-versus-tumor effect after allogeneic hematopoietic stem cell transplantation. Regulatory T cells (Tregs) may reduce alloreactivity, the major component of the graft-versus-tumor effect. In the setting of donor lymphocyte infusion after hematopoietic stem cell transplantation, we postulated that Treg depletion could improve alloreactivity and likewise the graft-versus-tumor effect of donor T cells. The safety and efficacy of Treg-depleted donor lymphocyte infusion was studied in 17 adult patients with malignancy relapse after hematopoietic stem cell transplantation. All but one had previously failed to respond to at least one standard donor lymphocyte infusion, and none had experienced graft-versus-host disease. Two of the 17 patients developed graft-versus-host disease after their first Treg-depleted donor lymphocyte infusion and experienced a long-term remission of their malignancy. Four of the 15 patients who did not respond after a first Treg-depleted donor lymphocyte infusion received a second Treg-depleted donor lymphocyte infusion combined with lymphodepleting chemotherapy aimed to also eliminate recipient Tregs. All four developed acute-like graft-versus-host disease that was associated with a partial or complete and durable remission. In the whole cohort, graft-versus-host disease induction through Treg depletion was associated with improved survival. These results suggest that Treg-depleted donor lymphocyte infusion is a safe, feasible approach that induces graft-versus-host or graft-versus-tumor effects in alloreactivity-resistant patients. In patients not responding to this approach, the combination of chemotherapy-induced lymphodepletion of the recipient synergizes with the effect of Treg-depleted donor lymphocyte infusion. These findings offer a rational therapeutic approach for cancer cellular immunotherapy.
- 31 May 2010
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 95 (6) , 1042
L-asparaginase for adult CD20 positive B-cell precursor acute lymphoblastic leukemia
- 31 May 2010
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 95 (6) , 1042
L-asparaginase for adult CD20 positive B-cell precursor acute lymphoblastic leukemia